ReviewMedical sciences (Basel, Switzerland)2022
New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.
Review in Medical sciences (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- Heart Failure with Preserved Ejection Fraction in Women with Breast Cancer Prior to Cancer Treatment: Insights from a Cardio-Oncology Assessment.Journal of clinical medicine · 2026Article
- Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025Review
- Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.Breast cancer research and treatment · 2025Article
- Cardiovascular health in breast cancer patients: insight on BRCA1/2 mutations impact.Cardio-oncology (London, England) · 2025Article
- Review
- Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review.Systematic reviews · 2024Article
- Use of Olives-derived Phytochemicals for Prevention and Treatment of Atherosclerosis: An Update.Current topics in medicinal chemistry · 2024Review
- Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know.Reviews in cardiovascular medicine · 2023Review
- Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease.European journal of preventive cardiology · 2023Article
- Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.Current heart failure reports · 2023Review
- New Concepts in Cardio-Oncology.Cancer treatment and research · 2023Article
- CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review.Therapeutic advances in medical oncology · 2023Review
- Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study.Frontiers in oncology · 2023Article
- Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases are largely represented in patients with cancer and appear to be important side effects of cancer treatments, heavily affecting quality of life and leading to premature morbidity and death among cancer survivors. In particular, treatments for breast cancer have been shown to potentially play serious detrimental effects on cardiovascular health. This review aims to explore the available literature on breast cancer therapy-induced side effects on heart and vessels, illustrating the molecular mechanisms of cardiotoxicity known so far. Moreover, principles of cardiovascular risk assessment and management of cardiotoxicity in clinical practice will also be elucidated. Chemotherapy (anthracycline, taxanes, cyclophosphamide and 5-fluorouracil), hormonal therapy (estrogen receptor modulator and gonadotropin or luteinizing releasing hormone agonists) and targeted therapy (epidermal growth factor receptor 2 and Cyclin-dependent kinases 4 and 6 inhibitors) adverse events include arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery diseases due to different and still not well-dissected molecular pathways. Therefore, cardiovascular prevention programs and treatment of cardiotoxicity appear to be crucial to improve morbidity and mortality of cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.